EUVIMEDEUVIMED entdecken
Crossref

Adverse Impact of Pre‐Transplant Liver Dysfunction in Allogeneic Hematopoietic Cell Transplantation

Yukiko Misaki iD, Masaharu Tamaki, Ryu Yanagisawa iD, Noriko Doki, Naoyuki Uchida iD, Masatsugu Tanaka, Tetsuya Nishida, Masashi Sawa, Yuta Hasegawa, Shuichi Ota iD, Makoto Onizuka, Sakata-Yanagimoto Mamiko und 8 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Yukiko Misaki und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Liver Diseases. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although the hematopoietic cell transplantation (HCT)‐comorbidity index (HCT‐CI) score is associated with an increased risk of mortality after allogeneic HCT, it remains unclear how pre‐HCT liver dysfunction affects clinical outcomes. We retrospectively compared clinical HCT outcomes among four groups stratified according to the presence of HCT‐CI liver and other organ scores, using a Japan transplant registry database between 2010 and 2020. Of the 14235 recipients, 1527 tested positive for an HCT‐CI liver score including HBV or HCV hepatitis ( n = 503). The 5‐year overall survival (OS) was significantly lower in the HCT‐CI liver(+) other(+) and HCT‐CI liver(−) other(+) groups compared to the HCT‐CI liver(+) other(−) and HCT‐CI liver(−) other(−) groups [49.9% vs. 59% vs. 66.5% vs. 68.3%, p < 0.001]. A multivariate analysis showed that both the HCT‐CI liver(+) other(+) [HR 1.62, p < 0.001] and HCT‐CI liver(−) other(+) groups [HR 1.21, p < 0.001] were significantly associated with inferior OS. Similarly, both the HCT‐CI liver(+) other(+) [HR 1.89, p < 0.001] and liver(−) other(+) groups [HR 1.26, p < 0.001] were significantly associated with an increased risk of NRM. On the other hand, the HCT‐CI liver(+) other(−) group was not associated with either OS or NRM. Separately analyzing the subcohorts with or without HCT‐CI other scores, the presence of an HCT‐CI liver score alone did not affect survival, while the co‐presence of pretransplant liver dysfunction seemed to synergistically increase the adverse impact on OS and NRM among recipients with other organ comorbidities. Further studies will be needed to identify optimal strategies for recipients with pretransplant liver dysfunction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLiver DiseasesHumansMaleFemaleMiddle AgedRetrospective StudiesAdultAgedTransplantation, HomologousJapanSurvival RateRegistries

Stichwörter der Autor:innen

HCT‐CIallogeneic hematopoietic cell transplantationhematopoietic stem cell transplantationhepatic dysfunctionpre‐transplant liver dysfunction

Autor:innen und Institutionen

  • Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Division of Emerging Medicine for Integrated Therapeutics (EMIT), Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Japan.
  • Division of Blood Transfusion, Shinshu University Hospital, Matsumoto, Japan.
  • Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
  • Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.

ORCID-Profile: Yukiko Misaki, Ryu Yanagisawa, Naoyuki Uchida, Shuichi Ota, Noboru Asada, Junya Kanda, Yoshinobu Kanda, Kimikazu Yakushijin, Hideki Nakasone

Zitieren

APA

Misaki, Y., Tamaki, M., Yanagisawa, R., Doki, N., Uchida, N., Tanaka, M., Nishida, T., Sawa, M., Hasegawa, Y., Ota, S., Onizuka, M., Mamiko, S. Y., Katayama, Y., Asada, N., Kanda, J., Fukuda, T., Atsuta, Y., Kanda, Y., Yakushijin, K., & Nakasone, H. (2025). Adverse Impact of Pre‐Transplant Liver Dysfunction in Allogeneic Hematopoietic Cell Transplantation. American Journal of Hematology. https://doi.org/10.1002/ajh.27652

Vancouver

Misaki Y, Tamaki M, Yanagisawa R, Doki N, Uchida N, Tanaka M, et al. Adverse Impact of Pre‐Transplant Liver Dysfunction in Allogeneic Hematopoietic Cell Transplantation. American Journal of Hematology. 2025. doi:10.1002/ajh.27652

BibTeX
@article{Misaki2025,
  author = {Misaki, Yukiko and Tamaki, Masaharu and Yanagisawa, Ryu and Doki, Noriko and Uchida, Naoyuki and Tanaka, Masatsugu and Nishida, Tetsuya and Sawa, Masashi and Hasegawa, Yuta and Ota, Shuichi and Onizuka, Makoto and Mamiko, Sakata-Yanagimoto and Katayama, Yuta and Asada, Noboru and Kanda, Junya and Fukuda, Takahiro and Atsuta, Yoshiko and Kanda, Yoshinobu and Yakushijin, Kimikazu and Nakasone, Hideki},
  title = {Adverse Impact of Pre‐Transplant Liver Dysfunction in Allogeneic Hematopoietic Cell Transplantation},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27652}
}
Kostenlos starten →